Ofatumumab just before the EULAR 2013 meeting

Right after the ACR meeting in 2011 I  had written "Ofatumumab is an anti-CD20 MAB, but nothing on ofatumumab at the ACR 2011. This seems strange as M. Østergaard and colleagues published a study in 2010." Link: http://rheumatologe.blogspot.de/2011/12/b-cell-depletion-and-other-b-cell.html
In June 2012 I had to state: "I haven´t seen anything new on ofatumumab, ocrelizumab and veltuzumab." http://rheumatologe.blogspot.de/2012/06/anti-cd-20-monoclonal-antibody.html
Now it's a week before the EULAR meeting 2013 opens and I've been notified of the following study. Regina Kurrasch and colleagues published: "Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics". In this study they concluded: "Treatment of RA patients with SC ofatumumab doses of 30 mg or higher resulted in profound and prolonged B cell depletion in blood. Single doses up to 60 mg were tolerated without glucocorticoid premedication. (ClinicalTrials.gov identifier NCT00686868)". Link: http://jrheum.org/content/early/2013/05/29/jrheum.121118.abstract 
That would make it a true competitor against rituximab! I hope that the EULAR 2013 meeting will bring more information than this phase 1/2 study.